UK and US spearhead search for drugs targeting RAS mutations
pharmaphorum media | April 20, 2017
Cancer Research UK and its Cancer Research Technology Pioneer Fund have joined with the US National Cancer Institute (NCI) to test new molecules targeting RAS mutations. These are “undruggable” mutations that often drive aggressive, hard to treat diseases including pancreatic and lung cancer.